Jane M. Grant-Kels MD, FAAD
Professor of Dermatology, Pathology, and Pediatrics; Vice Chair, Department of Dermatology; Director, Cutaneous Oncology and Melanoma Program; University of Connecticut Health Center and School of Medicine, Farmington, Connecticut; Adjunct Professor of Dermatology, University of Florida, Gainesville, FloridaDr. Jane Grant-Kels is Professor and founding Chair of the Department of Dermatology at the University of Connecticut (UCONN) Health Center and Medical School. She remains the founding Director of the Cutaneous Oncology Center and the Melanoma Program. Additionally, she is an Adjunct Professor of Dermatology at the University of Florida in Gainesville.
Dr. Grant-Kels specializes in cutaneous oncology and pigmented lesions of the skin. She founded the dermatology department at UCONN. She was instrumental in the development of the Women’s Health Center at UCONN and, most recently, initiated a Cutaneous Oncology Center within the Neag Cancer Center and Department of Dermatology.
Dr. Grant-Kels received her medical degree from Cornell University Medical College in New York. She trained in pediatrics and dermatology at the New York Hospital of Cornell Medical Center. She then completed a dermatopathology fellowship at New York University Medical Center.
Disclosures
- Advisory board and Chief Medical Officer: Veradermics
- Medical advisor: DermaSensor
Recent Contributions to PracticeUpdate:
- Total-Body Examination Versus Lesion-Directed Skin Cancer Screening
- Vitiligo and Tumor Response in Metastatic Melanoma Treated With Pembrolizumab
- Features of Combined Cutaneous Squamous Cell Carcinoma/Neuroendocrine Cell Carcinoma
- Comparison of Margin Status With Punch Biopsy vs Shave Biopsy
- Complete Response Rate in Cutaneous Metastatic Melanoma Treated With Intralesional IL-2, Imiquimod, and Topical Retinoid Combination Therapy
- Survival Outcomes in Patients With Multiple Primary Melanomas
- 2014 Top Stories in Dermatology: Melanoma
- Risk Factors for Late Metastases in Melanoma Patients Disease-Free More Than 10 Years
- No Prognostic Implication for De Novo vs Nevus-Associated Melanoma
- Low Clinical Utility to Re-Excising Non-Severe Dysplastic Nevi